About Archer

Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in targeted drug discovery for Alzheimer’s disease. Led by Chief Executive Officer and Chief Scientific Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer and Associate Chief Scientific Officer Fiona Crawford, Ph.D., Archer was created based on the groundbreaking research conducted at the Roskamp Institute in Sarasota, Florida.

Included in this research is clinical development of Nilvadipine as a therapeutic for Alzheimer’s Disease. A Phase I/IIA human clinical trial was conducted in Alzheimer’s patients in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland. This trial showed that Nilvadipine was well-tolerated in Alzheimer’s disease patients, and, together with extensive preclinical data in laboratory models of Alzheimer’s Disease, laid the foundation for a Phase III double-blind, placebo-controlled clinical trial of Nilvadipine (NILVAD) which is currently ongoing in Europe (The NILVAD Study).

Our Mission
Archer and its world-class team of researchers and scientists are committed to identifying quality therapeutics and using their uniquely pure focus to find a cure for Alzheimer’s disease.

Our Strategy
Armed with extensive experience in amyloid biology, neuroinflammation and neurodegenerative diseases, the Archer team has a pipeline of multi-modal products that tackle Alzheimer’s Disease pathogenesis. The Archer strategy is two-fold:

  1. To take existing drugs with known safety profiles into the clinic for the new indication, Alzheimer’s disease.
  2. To use these drugs and related drugs as templates for the development of new, more effective drugs.

Our Motivation
Currently there are approximately 5.2 million Americans and 18 million people worldwide of all ages who have Alzheimer’s disease, with approximately 13 percent of those persons of the age 65 and older. By 2025, the number of people age 65 and older in the US with Alzheimer's disease is estimated to reach 7.1 million—a 40 percent increase from the 5 million age 65 and older currently affected. By 2050, the US population effected by Alzheimer's disease may nearly triple, from 5 million to a projected 13.8 million (over 46 million worldwide), barring the development of medical breakthroughs to prevent, slow or stop the disease. (Alzheimer's Association, 2015, Alzheimer's Disease International, 2015).

It is with these alarming statistics and the unmet demand for effective therapeutics, that Archer is committed to specializing in identifying new treatments for Alzheimer’s disease.